tiprankstipranks

Aclaris Therapeutics assumed with an Overweight at Cantor Fitzgerald

Aclaris Therapeutics assumed with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage of Aclaris Therapeutics (ACRS) with an Overweight rating. Cantor is bullish on the TSLP and IL-4R bispecific, which looks differentiated, and even early proof-of-concept data for this asset could lead to substantial upside, the analyst tells investors in a research note. The firm also believes significant value can be unlocked for ATI-045 in asthma and other large respiratory indications after upcoming China Phase 2 data.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue